Pluri Inc. 8-K Summary: July 11, 2023
Business Context and Reporting Period
This Form 8-K was filed by Pluri Inc. on July 11, 2023, reporting a significant corporate event under Item 8.01 (Other Events). The Company, incorporated in Nevada and headquartered in Haifa, Israel, operates in the biotechnology sector focusing on cell therapy.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The primary financial disclosure is a new contract award:
- New Contract Value: $4.2 million
- Contract Duration: Three years
- Funding Source: U.S. National Institute of Allergy and Infectious Diseases (NIAID)
Material Changes
The material change reported is the execution of a three-year agreement to advance the development of PLX-R18, a cell therapy candidate for Hematopoietic Acute Radiation Syndrome (H-ARS). This represents a new revenue stream and strategic partnership rather than a change in historical financial performance.
Outlook, Management Commentary, and Risks
Management Commentary: The Company will collaborate with the U.S. Department of Defense Armed Forces Radiobiology Research Institute (AFRRI) and the Uniformed Services University of Health Sciences (USUHS). The program is funded by NIAID as part of the National Institutes of Health.
Risks and Contingencies: The filing does not explicitly detail risks associated with this specific contract, though standard biotechnology development risks (e.g., clinical trial failure, regulatory approval) apply to the advancement of PLX-R18.
Key Facts for Investor Verification
- Verify the specific milestones and payment terms within the $4.2 million NIAID contract.
- Confirm the current development stage of the PLX-R18 cell therapy candidate.
- Assess the impact of this contract on the Company's overall cash runway and liquidity position.
- Review the roles and responsibilities of the collaborating partners (AFRRI and USUHS).